Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Oramed Pharmaceuticals (ORMP) EBT Margin (2016 - 2025)

Oramed Pharmaceuticals filings provide 8 years of EBT Margin readings, the most recent being 352.9% for Q1 2025.

  • Quarterly EBT Margin changed N/A to 352.9% in Q1 2025 from the year-ago period, while the trailing twelve-month figure was 3766.2% through Dec 2025, changed N/A year-over-year, with the annual reading at 3766.2% for FY2025, N/A changed from the prior year.
  • EBT Margin hit 352.9% in Q1 2025 for Oramed Pharmaceuticals, down from 194.81% in the prior quarter.
  • Across five years, EBT Margin topped out at 194.81% in Q2 2023 and bottomed at 1693.92% in Q2 2022.
  • Average EBT Margin over 4 years is 996.01%, with a median of 949.66% recorded in 2021.
  • Peak annual rise in EBT Margin hit 149911bps in 2023, while the deepest fall reached 90751bps in 2023.
  • Oramed Pharmaceuticals' EBT Margin stood at 850.5% in 2021, then tumbled by -59bps to 1355.64% in 2022, then soared by 86bps to 194.81% in 2023, then tumbled by -81bps to 352.9% in 2025.
  • Per Business Quant, the three most recent readings for ORMP's EBT Margin are 352.9% (Q1 2025), 194.81% (Q2 2023), and 781.98% (Q1 2023).